About
BIOCYTOGEN

Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). 
About the Company banner

  • 2025

    New Office Opening
    Our Journey of Innovation and Growth

    Every step we take brings us closer to our mission: enabling breakthroughs that make a difference. Join us in shaping the future of healthcare, one innovation at a time.

    New Office Opening March
    Biocytogen Expands Global Reach with New San Diego Office

    Biocytogen (“Biocytogen,” HKEX: 02315), a global biotech company advancing antibody-based drug discovery with innovative technologies, is pleased to announce the opening of its new office in San Diego, California, reinforcing its commitment to becoming the "global headstream of new drugs." This strategic expansion will enhance global partnerships in therapeutic antibody development and preclinical solutions, leveraging advanced technologies to accelerate the development of transformative therapeutics.

    Read more

  • 2023

    Product Launch
    & New Office Opening
    Product Launch & New Office Opening January
    Biocytogen Launches RenNano® Mouse

    Biocytogen officially launches its fully human heavy chain antibody platform, RenNano, the third member of the RenMice family.

    Read more May
    Biocytogen Opens San Francisco Office to Accelerate Globalization

    Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) has announced the opening of a new office in San Francisco, California, USA. The new space will aim to accelerate the globalization of Biocytogen's businesses.

    Read more Product Launch & New Office Opening 2 August
    Biocytogen Announces Grand Opening of Waltham, MA Facility

    Biocytogen Pharmaceuticals announced the grand opening of a new 37,000 sqft. facility in Waltham, MA for its US-based subsidiary, Biocytogen Boston Corporation.

    Read more

  • 2022

    Expansion & HKEX Listing
    Expansion & HKEX Listing March
    Grand Opening in Germany!

    Announced the opening of the Biocytogen Europe Innovation Center (BEIC) in Heidelberg, Germany.

    September
    Biocytogen's Listing Ceremony

    Biocytogen announced the company's official listing on the Main Board of the Stock Exchange of Hong Kong. Government representatives, shareholders, agencies, collaborative partners, and employee representatives attended the listing ceremony.

  • 2021

    New Financing
    & Clinical Trials
    New Financing & Clinical Trials June
    Tens of Millions in Financing

    Completed a new round of financing totaling tens of millions of dollars

    June
    YH001 & YH003 Phase II Clinical Trials

    Obtained approval from the FDA to commence Phase II clinical trials for YH001 and YH003 in the U.S.

  • 2020

    Clinical Trials
    & Platform Launch
    Clinical Trials & Platform Launch January
    YH002 Clinical Trials Approved in U.S.

    Anti-OX40 antibody YH002 was approved for clinical trials in the United States

    March
    RenMice HiTS Platform Launch

    RenMice HiTS Platform initiative launched, signifying Biocytogen's transformation to a biotechnology company

    May
    YH001 & YH002 Approved

    Anti-CTLA-4 and OX40 antibodies YH001 and YH002 approved for clinical trials in China

    August
    Biocytogen & Eucure

    Biocytogen merges with Eucure Biopharma, aiming to create innovative antibody drugs to improve human health worldwide.

    September
    RenMice HiTS Platform Financing

    Completion of D+ round financing, enabling progression of the RenMice HiTS Platform initiative

  • 2019

    New Technology
    & Clinical Trials
    New Technology & Clinical Trials August
    RenMab Platform Launched

    Developed RenMab Mouse, a fully human antibody mouse model; Closed D-round funding in July

    October
    YH001 Clinical Trials Approved in U.S.

    Anti-CTLA-4 antibody YH001 was approved for clinical trials in the United States

  • 2018

    New Sites & Scaling Up
    New Sites & Scaling Up February
    Biocytogen Boston Incorporated

    Boston and Shanghai sites opened for business

    April
    Venture Funding

    Received C-round funding from SDIC Venture Capital, 3E Bioventures, Cowin Capital Group and Oriza Holdings

  • 2016

    Company Expansion
    Company Expansion
    Haimen Animal Center Opens

    Haimen Animal Center began operations; AAALAC accreditation earned; Antibody Discovery Service Platform established; B-NDG™ and a comprehensive variety of humanized immune checkpoint mice were supplied to clients

  • 2015

    Pharmacology Platform
    Pharmacology Platform
    Preclinical Services & New Funding

    Established preclinical services platform; Raised B-round funding from SDIC Venture Capital and BioVeda China Fund

  • 2014

    Mouse Models
    Mouse Models
    Developed Humanized Immune-checkpoint Mice and B-NDG Mice

    Developed B-NDG™ mice (highly immune deficient) and B-hPD-1, the first humanized immune-checkpoint mouse model

  • 2011

    Gene Editing
    Gene Editing
    Established Gene Editing Platform

    Developed ESC/HR-based gene editing technology platform and delivered gene editing services to our first customer.

  • 2009

    Origins
    Origins
    Beijing Biocytogen Established

    Beijing Biocytogen was established to commence research and development of biotechnology in China.

  • 2008

    Founded in Massachusetts
    Founded in Massachusetts, USA

    Biocytogen was founded in Massachusetts in 2008